By: Dr. Sebastián Marincolo, Director of Strategic Content & Editorial, Weed.de

Germany’s partial cannabis legalisation was originally designed to undercut the black market. It was also designed to protect the country’s youth and shield consumers from unsafe products.

The original reform plan envisioned nationwide retail stores, but these were dropped quickly after EU Commission objections. In their place came the two-pillar model: Pillar 1 legalised home cultivation and cannabis social clubs (Anbauvereinigungen), while Pillar 2 set up regional five-year scientific pilot projects, allowing licensed retailers to sell cannabis products to adult participants.

Pillar 2 was deferred for separate legislation that has yet to materialise. Critics argued that without retail infrastructure, the black market would persist unchallenged.

But they were wrong. Surprisingly, even this incomplete reform is succeeding: the EKOCAN evaluation, the federally mandated assessment of the Konsumcannabisgesetz (KCanG), shows the legal market expanding, youth consumption stable, cannabis-related crime declining, and crucially, the black market beginning to shrink (EKOCAN, 2025).

But peer-reviewed research reveals an unintended consequence: medical cannabis patients now face higher rates of stigmatisation than recreational users. This paradox exposes why the reform remains incomplete, and why Pillar 2 is no longer optional.

The Counterintuitive Finding

A September 2025 study in the Journal of Cannabis Research found that 47.1% of medical-only cannabis users reported perceived stigmatisation, compared to significantly lower rates among recreational users (Rosenkranz et al., 2025).

The same pattern held for self-stigma: 41.9% of medical users experienced internalised shame about their cannabis use.

This finding defies intuition. These are patients using authorised medicine under physician supervision. Yet the study’s authors note that the public still perceives cannabis primarily as ‘an illegal drug and not a medicine,’ leading patients to feel ashamed of using ‘a drug’ rather than ‘a medicine’ for symptom relief.

A separate qualitative study in BMC Public Health confirms this dynamic: patients reported being dismissed by healthcare providers, facing workplace discrimination, and encountering police who could not distinguish between medical and recreational use (Borojevic & Söhner, 2025).

Dr. Sebastián Marincolo

The Single-Door Problem: By the Numbers

The root cause is structural. Germany’s reform technically created three legal pathways: the medical system, home cultivation, and cannabis social clubs (cannabis associations).

In practice, however, only the medical route functions at scale. Home cultivation requires space, expertise, equipment, and upfront investment, barriers that exclude millions of Germans living in small apartments or rental housing.

Cannabis social clubs faced protracted licensing delays; although 337 have now received approval as of October 2025, with an average membership of 275 people, they serve approximately 92,000 members – just 2% of Germany’s estimated 4.5 million cannabis users (BCAv, 2025; International CBC, 2025; Bundesgesundheitsministerium, 2025).

This leaves the medical system as the only viable legal pathway for most adults, a system now absorbing demand it was never designed to meet.

Research suggests this includes a substantial population of self-medicators. The Canadian Cannabis Survey 2020 found that 76% of people who use cannabis for medical purposes do not have authorisation from a health care professional – they are self-medicating for conditions like chronic pain, anxiety, and sleep disorders (Health Canada, 2021).

This pattern of unauthorised therapeutic use is consistent across jurisdictions and reflects a widespread phenomenon of individuals seeking symptom relief outside formal medical channels.

Telemedicine platforms have helped lower access barriers for patients struggling to find knowledgeable prescribing physicians.

According to official BfArM data, Germany imported approximately 142 tonnes of medical cannabis in the first three quarters of 2025, on track to exceed 190 tonnes by year’s end, a nearly sixfold increase from 2023, when imports totalled 32.5 tonnes (BfArM, 2025).

Critics suspect the surge in prescriptions reflects widespread abuse by healthy adults.

The reality is mostly different, and more nuanced: lowered barriers have definitely helped cannabis-naïve patients with severe illnesses access treatment; thousands of self-medicators have finally obtained proper medical guidance; and yes, some non-medical users access the medical channel because the regulated recreational market they were promised years ago never materialised.

The consequence is stigma flowing in both directions: patients dismissed as recreational users seeking legal cover, and responsible adults forced to ‘perform illness’ to access a regulated product.